A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma
Status:
Terminated
Trial end date:
2016-07-06
Target enrollment:
Participant gender:
Summary
The goal of the Phase I portion of this study is to find the highest tolerable dose of TPI
287 that can be given in combination with Temodar (temozolomide) to patients with metastatic
melanoma.
The goal of the Phase II portion of this study is to learn if TPI 287, given in combination
with temozolomide, can control metastatic melanoma. The safety of this combination will also
be studied. NOTE: Study stopped before progressing to Phase II portion.